Company Caplin Point Laboratories Ltd NSE India S.E.
Stocks
INE475E01018
Pharmaceuticals
|
End-of-day quote
NSE India S.E.
|
||
| - INR | - |
|
| 08-14 | Caplin Point Laboratories Limited, Q1 2027 Earnings Call, Aug 12, 2026 | |
| 08-12 | Caplin Point Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 | CI |
Business description: Caplin Point Laboratories Ltd
Sales by Activity: Caplin Point Laboratories Ltd
| Fiscal Period: March | 2022 (INR) | 2023 (INR) | 2024 (INR) | 2025 (INR) | 2026 (INR) |
|---|---|---|---|---|---|
Pharmaceutical Formulations | 12.71B | 14.68B | 16.96B | 19.4B | - |
Geographical breakdown of sales: Caplin Point Laboratories Ltd
| Fiscal Period: March | 2022 (INR) | 2023 (INR) | 2024 (INR) | 2025 (INR) | 2026 (INR) |
|---|---|---|---|---|---|
Unallocated | - | - | - | 964M | - |
Rest of The World | - | - | - | 15.83B | - |
United States of America (USA) | - | 2.05B | 3.05B | 3.55B | - |
Latin America | - | 12.17B | 13.55B | - | - |
Africa | - | 440M | 339M | - | - |
Executive Committee: Caplin Point Laboratories Ltd
| Manager | Title | Age | Since |
|---|---|---|---|
Sridhar Ganesan
CEO | Chief Executive Officer | 71 | 2015-03-27 |
D. Muralidharan
DFI | Director of Finance/CFO | - | 2016-02-18 |
Anto V.
ADM | Chief Administrative Officer | - | - |
Gunasakaran S.
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Compliance Officer | - | 2022-06-24 |
Composition of the Board of Directors: Caplin Point Laboratories Ltd
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 73 | 2010-01-26 | |
| Director/Board Member | - | 2025-11-04 | |
Sridhar Ganesan
BRD | Director/Board Member | 71 | 2015-03-27 |
D. Muralidharan
BRD | Director/Board Member | - | 2026-08-11 |
R. Nagendran
BRD | Director/Board Member | - | 2022-09-28 |
S Deenadhayalan
BRD | Director/Board Member | - | 2022-09-28 |
| Director/Board Member | 76 | - | |
| Director/Board Member | - | 2025-11-04 | |
| Director/Board Member | - | 2014-08-24 | |
Susan Mathews
BRD | Director/Board Member | - | 2026-01-30 |
Company details: Caplin Point Laboratories Ltd
Caplin Point Laboratories Ltd.
No. 3 Ashvich Towers
600096, Chennai
+91 44 2496 8000
http://www.caplinpoint.net
Group companies: Caplin Point Laboratories Ltd
| Name | Category and Sector |
|---|---|
Caplin Steriles Ltd.
 Caplin Steriles Ltd. Pharmaceuticals: MajorHealth Technology Manufactures injectable pharmaceutical products |
Pharmaceuticals: Major
|
Caplin Onco Ltd. |
Generic Pharmaceuticals
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.21% | -1.30% | +18.91% | +65.89% | 48.26B | |
| -2.49% | -3.62% | +42.16% | +110.97% | 40.5B | |
| +0.72% | -2.00% | -10.20% | +11.00% | 11.85B | |
| +3.29% | -2.86% | +14.11% | +81.79% | 11.83B | |
| -1.50% | -1.50% | +24.76% | +142.59% | 9.36B | |
| -0.86% | -4.94% | +23.76% | +42.73% | 7.5B | |
| -1.23% | -1.57% | +39.31% | -13.47% | 7.37B | |
| +0.60% | -2.51% | +19.49% | +209.21% | 7.28B | |
| -0.32% | -2.67% | -46.31% | +18.10% | 5.19B | |
| Average | -0.22% | -2.35% | +14.00% | +74.31% | 16.57B | |
| Weighted average by Cap. | -0.61% | -1.85% | +21.91% | +80.10% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- CAPLIPOINT Stock
- Stock
- Company Caplin Point Laboratories Ltd
Select your edition
All financial news and data tailored to specific country editions
